Metabolic Impacts of Antiepileptic Drugs in Epilepsy Management

Antiepileptic drugs (AEDs) are central to seizure control but exert diverse effects on metabolic pathways that influence long-term health. Enzyme-inducing AEDs accelerate hepatic cytochrome P450 activity, altering lipid and steroid hormone metabolism, and have been linked to dyslipidaemia, vitamin D deficiency and bone demineralisation. Non-enzyme-inducing agents generally have a more benign enzyme profile but may still provoke weight gain, insulin resistance and mitochondrial dysfunction through off-target effects on adipocyte differentiation and oxidative phosphorylation. Certain older drugs, notably valproic acid, promote hepatic steatosis and adverse lipid profiles, whereas newer agents such as lamotrigine and levetiracetam tend to preserve glucose and lipid homoeostasis. The balance between seizure suppression and metabolic safety is shaped by drug-specific pharmacokinetics, patient age, comorbidities and genetic determinants of enzyme activity. Recognition of these impacts has driven recommendations for regular monitoring of weight, fasting lipids, glucose tolerance and bone density, and for tailoring drug choice to minimise cardiovascular and endocrinological risks without compromising antiepileptic efficacy.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Metabolic Impacts of Antiepileptic Drugs in Epilepsy Management publication trend

The graph below shows the total number of articles in metabolic impacts of antiepileptic drugs in epilepsy management across all publications each year (not limited to Nature Index journals).

Technical terms

Dyslipidaemia: An abnormal concentration or composition of lipids in the blood, often manifesting as elevated cholesterol or triglycerides, which increases cardiovascular risk.

Enzyme-inducing antiepileptic drug: A medication that upregulates hepatic cytochrome P450 enzymes, accelerating metabolism of endogenous and exogenous substrates and potentially altering lipid and hormone levels.

Insulin resistance: A state in which cells fail to respond adequately to insulin, leading to impaired glucose uptake, hyperglycaemia and compensatory hyperinsulinaemia.

Therapeutic range: The plasma concentration interval within which a drug is expected to achieve clinical efficacy with minimal toxicity.

References

1. Association of antiseizure medications and adverse cardiovascular events: A global health federated network analysis. Epilepsia (2024).
2. Pre-treatment risk predictors of valproic acid-induced dyslipidemia in pediatric patients with epilepsy. Frontiers in Pharmacology (2024).
3. Epilepsy, antiepileptic drugs, and the risk of major cardiovascular events. Epilepsia (2021).
4. Lipidomic characteristics and clinical findings of epileptic patients treated with valproic acid. Journal of Cellular and Molecular Medicine (2019).